二吲哚基马来酰亚胺XI盐酸盐 | 145333-02-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 二吲哚基马来酰亚胺XI盐酸盐
• 英文名称: Ro 31-8830 (hydrochloride)
• 英文别名: 3-[8-[(dimethylamino)methyl]-6,7,8,9-tetrahydropyrido[1,2-a]indol-3-yl]-4-(1-methylindol-3-yl)pyrrole-2,5-dione;hydrochloride
• CAS: 145333-02-4
• 化学式: C28H29ClN4O2
• 分子量: 489.0
• InChiKey: WMVQGKBSNAIMHI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.25
• 重原子数：
  35
• 可旋转键数：
  4
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  59.3
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• PERKINSON DISEASE-RELATED GENE GRK5 AND USE THEREOF
  申请人：Hubit Genomix, Inc.

  公开号：EP1878804A1

  公开（公告）日：2008-01-16

  Large-scale SNP analyses conducted on subjects in a Parkinson's disease patient group and a normal control group led to the successful identification of a gene (GRK5) associated with Parkinson's disease. In addition, it was newly discovered that phosphorylation of α-synuclein is promoted by enhanced expression of the GRK5 gene, and as a result, the formation of soluble α-synuclein oligomers is promoted, leading to Parkinson's disease. The present invention enables the assessment of Parkinson's disease as well as the screening of therapeutic agents for Parkinson's disease using as an index the expression of GRK5 gene.

  通过对帕金森病患者组和正常对照组的受试者进行大规模 SNP 分析，成功鉴定出与帕金森病相关的基因（GRK5）。此外，还新发现 GRK5 基因的表达增强会促进 α-突触核蛋白的磷酸化，从而促进可溶性 α-突触核蛋白寡聚体的形成，导致帕金森病。本发明能够以 GRK5 基因的表达量为指标，对帕金森病进行评估，并筛选出治疗帕金森病的药物。
• Parkinson's Disease-Related Gene GRK5 and Uses Thereof
  申请人：Kato Takeo

  公开号：US20090255001A1

  公开（公告）日：2009-10-08

  Large-scale SNP analyses conducted on subjects in a Parkinson's disease patient group and a normal control group led to the successful identification of a gene (GRK5) associated with Parkinson's disease. In addition, it was newly discovered that phosphorylation of α-synuclein is promoted by enhanced expression of the GRK5 gene, and as a result, the formation of soluble α-synuclein oligomers is promoted, leading to Parkinson's disease. The present invention enables the assessment of Parkinson's disease as well as the screening of therapeutic agents for Parkinson's disease using as an index the expression of GRK5 gene.